Bain Capital in Talks to Buy Mitsubishi Tanabe Pharma
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2025
0mins
Should l Buy ?
Source: WSJ
Bain Capital Acquisition Talks: Bain Capital is negotiating to acquire Mitsubishi Chemical's pharmaceutical business, specifically Mitsubishi Tanabe Pharma.
Deal Value: The potential deal could exceed 500 billion yen, which is approximately $3.21 billion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
